Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, oph...
Abpro Holdings Received Notice of Delisting
Abpro Holdings 10-K: $0 revenue, $(1.30) EPS on $2.89M net loss
Abpro Holdings, Inc. | 10-K: FY2025 Revenue: USD 0
US Stock Movement Update: Abits surged 163.29%, Rackspace Tech rose 64.49%, Twin Vee PowerCats fell 54.59%
U.S. stock market midday update: Abpro down 14% with increased trading volume, market sentiment fluctuates significantly, future trends need to be monitored
U.S. Stock Movement Update: Neo-Concept surged 115%, Quince Therapeutics rose 75%, Liminatus Pharma fell 52%